PharmaShots | Incisive News in 3 Shots

Subscribe Now

travere therapeutics

PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

March 15, 2024

Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)

Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)

March 12, 2024

Travere Therapeutics Report Results for Filspari in 2 P-III Trial for the Treatment of IgA Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS)

Travere Therapeutics Report Results for Filspari in 2 P-III Trial for the Treatment of IgA Nephropathy (IgAN) and Focal Segmental...

November 7, 2023

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy

February 21, 2023

Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

May 17, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us